Overview
Cardiology Regulatory Landscape
The regulatory environment for cardiology therapies involves specialized requirements from FDA Division of Cardiology and Nephrology, EMA Cardiovascular Working Party, PMDA Cardiovascular Review. This guide maps each requirement to ArcaScience's platform capabilities, demonstrating how AI-driven benefit-risk analysis aligns with and accelerates regulatory compliance.
Regulatory Requirements
Key Requirements by Agency
FDA Requirements
- ✓ Cardiovascular outcome trial requirements
- ✓ QT/QTc study guidance (ICH E14)
- ✓ Anti-thrombotic drug BRA expectations
- ✓ Heart failure drug development guidance
- ✓ Post-marketing REMS for CV drugs
EMA Requirements
- ✓ Cardiovascular safety assessment guidelines
- ✓ Thorough QT study requirements
- ✓ Heart failure clinical investigation guidance
- ✓ Anticoagulant/antiplatelet BRA expectations
PMDA Requirements
- ✓ Japan-specific CV safety monitoring
- ✓ QT assessment requirements
- ✓ Post-marketing CV surveillance obligations
ArcaScience Alignment
How ArcaScience Maps to Cardiology Requirements
Data Coverage
Cardiology-specific data from 47+ global sources, pre-harmonized and validated for regulatory submissions.
AI Models
Cardiology-trained AI models for adverse event classification, signal detection, and benefit quantification with regulatory validation.
Regulatory Outputs
Pre-formatted outputs aligned with FDA Division of Cardiology and Nephrology and EMA Cardiovascular Working Party submission requirements.
Download
Get the Full Cardiology Regulatory Landscape
Complete the form below to receive the document via email.
Related Resources